NDA 021108 · Valeant Pharms North
Renova
Tretinoin · Topical · Retinoid
Last checked: Nov 19, 2026Latest source record: May 25, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Aug 31, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
375
82 Phase 3, 25 recruiting
FAERS reports
6,666
4,154 serious, 856 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 24, 2026.
INDICATIONS AND USAGE (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) RENOVA (tretinoin cream) 0.02% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of fine facial wrinkles in patients who use comprehensive skin care and sunlight avoidance programs. RENOVA (tretinoin cream) 0.02% DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN. In double-blind, vehicle-controlled clinical studies, many patients in the vehicle group achieved desired palliative effects on fine wrinkling of facial skin with the use of comprehensive skin care and sunlight avoidance programs including sunscreens, protective clothing, and non-prescription emollient creams. • RENOVA (tretinoin cream) 0.02% has NOT DEMONSTRATED A MITIGATING EFFECT on significant signs of chronic sunlight exposure such as coarse or deep wrinkling, tactile roughness, mottled hyperpigmentation, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. • RENOVA (tretinoin cream) 0.02% should be used under medical supervision as an adjunct to a comprehensive skin care and sunlight avoidance program that includes the use of effective sunscreens (minimum SPF of 15) and protective clothing. • Patients with visible actinic keratosis and patients with a history of skin cancer were excluded from clinical trials of RENOVA (tretinoin cream) 0.02%. Thus the effectiveness and safety of RENOVA (tretinoin cream) 0.02% in these populations are not known at this time. • Neither the safety nor the effectiveness of RENOVA (tretinoin cream) 0.02% for the prevention or treatment of actinic keratoses or...
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- RENOVA · TRETINOIN 0.02% · CREAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tretinoin" as an intervention, any sponsor and status, largest first.
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT04353180 · 100,000 participants (planned) · Start Aug 2021 · Primary completion Oct 2021
Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment; Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment and 3 more · For: COVID19
Sites: Cairo, Egypt · 2 sites in all
- Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT05002530 · 10,000 participants (planned) · Start Nov 2021 · Primary completion Dec 2021
Drug: Aerosolized 13 cis retinoic acid plus Vitamin D; Aerosolized All trans retinoic acid plus Vitamin D · For: Post COVID-19 Anosmia (Loss of Smell)
Sites: Foshan, China; Kafr ash Shaykh, Egypt; Riyadh, Saudi Arabia
- Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid LeukemiaPivotal-lookingStatus unknown
Medical Research CouncilGovernment (non-federal)
NCT00002658 · 2,000 participants (planned) · Start Jan 1994
Drug: filgrastim; amsacrine and 8 more · For: Leukemia; Neutropenia
Sites: Cardiff, United Kingdom
- Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromePivotal-lookingCompleted
Leukemia Research FundAcademic, hospital or other
NCT00005823 · 2,000 participants (planned) · Start Dec 1998
Drug: cytarabine; daunorubicin hydrochloride and 7 more · For: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Sites: Birmingham, United Kingdom; London, United Kingdom; Cardiff, United Kingdom
- A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT GelPivotal-lookingCompleted
Stiefel, a GSK CompanyIndustry
NCT00689117 · 1,649 participants · Start Apr 2008 · Primary completion Apr 2009
Drug: CT Gel; Clindamycin Gel (clindamycin ) and 2 more · For: Acne Vulgaris; Acne
Sites: Birmingham, Alabama; Mobile, Alabama; Hot Springs, Arkansas · 32 sites in all
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00026312 · 1,449 participants · Start Oct 26, 2001 · Primary completion Jan 12, 2012
Drug: Aldesleukin; Dinutuximab and 2 more · For: Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma and 3 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 197 sites in all
- Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and PlaceboPivotal-lookingCompleted
Actavis Mid-Atlantic LLCIndustry
NCT01257906 · 1,225 participants · Start May 2010 · Primary completion Oct 2010
Drug: CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL; ZIANA® and 1 more · For: MILD TO SEVERE ACNE VULGARIS
Sites: Bangalore, India
- Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin CancerPivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00007631 · 1,131 participants · Start Mar 1998 · Primary completion Nov 2004
Drug: Tretinoin 0.1% cream or placebo · For: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Skin Neoplasms
Sites: Phoenix, Arizona; Long Beach, California; Miami, Florida · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use885
- drug ineffective747
- pain499
- product use in unapproved indication483
- vomiting452
- paraesthesia376
- abdominal pain upper368
- rash367
- nausea353
- diarrhoea350
- headache339
- maternal exposure during pregnancy339
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 38 |
| 2005 | 33 |
| 2006 | 28 |
| 2007 | 40 |
| 2008 | 115 |
| 2009 | 76 |
| 2010 | 80 |
| 2011 | 95 |
| 2012 | 160 |
| 2013 | 106 |
| 2014 | 150 |
| 2015 | 246 |
| 2016 | 364 |
| 2017 | 358 |
| 2018 | 473 |
| 2019 | 364 |
| 2020 | 383 |
| 2021 | 430 |
| 2022 | 510 |
| 2023 | 569 |
| 2024 | 676 |
| 2025 | 810 |
| 2026 | 562 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Guidelines of care for the management of acne vulgaris.
Reynolds RV, Yeung H, Cheng CE, et al. · J Am Acad Dermatol 2024 · Practice Guideline, Systematic Review
- Management of androgenic alopecia: a systematic review of the literature.
Rosenthal A, Conde G, Greco JF, et al. · J Cosmet Laser Ther 2024 · Systematic Review
- Melasma Treatment: An Evidence-Based Review.
McKesey J, Tovar-Garza A, Pandya AG · Am J Clin Dermatol 2020 · Systematic Review
- Treatment of Solar Lentigines: A Systematic Review of Clinical Trials.
Mardani G, Nasiri MJ, Namazi N, et al. · J Cosmet Dermatol 2025 · Systematic Review
- Wrinkles.
Manríquez JJ, Majerson Gringberg D, Nicklas Diaz C · BMJ Clin Evid 2008 · Systematic Review
- Comparing Tretinoin to Other Topical Therapies in the Treatment of Skin Photoaging: A Systematic Review.
Siddiqui Z, Zufall A, Nash M, et al. · Am J Clin Dermatol 2024 · Systematic Review, Comparative Study
Sponsor: Valeant Pharms North
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.